布地奈德联合特布他林雾化吸入治疗哮喘的临床疗效及对肺功能的影响

目的探讨布地奈德联合特布他林雾化吸入治疗小儿哮喘的临床疗效及对肺功能的影响。方法2005年7月至2007年7月86例支气管哮喘患儿，随机分为两组，观察组45倒，采用布地奈德联合特布他林治疗：对照组41例，单独采用布地奈德治疗。结果观察组的总有效率明显高于对照组，两组比较差异有统计学意义（P〈0．05）。观察组咳嗽消失、喘息消失及哮鸣音消失时间均明显短于对照组，差异均有统计学意义（P〈0．05）。对照组治疗后FEV1、FEV1％-5治疗前比较，差异无统计学意义（P〉O．05）。观察组治疗后FEV1、FEV1％都较治疗前明显升高，差异有统计学意义（P〈0．05）；并且观察组FEV1、FEV1％都较对照组升高明显，差异有统计学意义（P〈0．05）。结论布地奈德联合特布他林雾化吸入治疗哮喘的疗效显著，肺功能状态改善明显，不良反应少，是治疗咳嗽变异型哮喘的有效方法．

Clinical curative effect of combined treatment with budesonide and terbutaline for asthma and its impaction on pulmonary function

OBJECTIVE To study the curative effect of combined treatment with budesonide and terbutaline for asthma and its impaction on pulmonary function. METHODS From July 2005 to July 2007, 86 cases with child asthma were randomly classified into two groups. Observation group with 45 cases were treated with budesonide and terbutaline, while control group with 41 cases were treated with budesonide. RESULTS The effective rate in observation group was significantly higher than that in control group （P 〈 0.05）. The extinction time of cough, gasping and wheezing rale in observation group were shorter than those in control group （P 〈 0.05）. In group, there were no significant differences in FEV1 and FEV1% between the pre-treatment and post-treatment （P 〉0.05）. In observation group, FEV1 and FEV1% post-treatment were higher than those in pre-treatment （P 〈0.05）. Moreover, the improvements of FEV1 and FEV1 % in observation group were significantly higher than those in control group （P 〈 0.05）. CONCLUSION Combined treatment with budesonide nd terbutaline for children cough variant asthma can improve the clinical efficacy and pulmonary status, which is an effective method for cough variant asthma.